Filing Flows › Iovance Biotherapeutics (IOVA) › Q2 2025
Iovance Biotherapeutics (IOVA) Q2 2025 earnings results (second quarter 2025)
10-Q filed Aug 7, 2025
Iovance Biotherapeutics (IOVA) reported revenue of $60.0M for the second quarter 2025 (Q2 2025), +93% from a year earlier and +22% from the quarter before. Operating margin was -189.8%, net loss $112M (186.2% of revenue).
Iovance Biotherapeutics, Q2 2025: revenue $60.0M (+93% year over year), operating margin -189.8%, net loss $112M, operating cash flow −$67.4M. The chart follows the revenue to costs, profit and cash.
| Q2 2025 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $60.0M | +22% | +93% |
| Operating profit | −$114M | — | — |
| Net earnings | −$112M | — | — |
| Operating cash flow | −$67.4M | — | — |
What changed
Revenue was $60.0M in Q2 2025, up 93% year over year and up 22% from the previous quarter. Amtagvi was the largest line at 90% of revenue. Amtagvi added $41.3M year over year (up 322%), 143% of the total change. PROLEUKIN declined 68%.
Operating costs exceeded revenue by $113.8M, an operating margin of -189.8%. Total costs grew 31% against revenue growth of 93%. The fastest-growing cost line was Cost of revenue (+81%). The quarter ended with a net loss of $111.7M, narrower than the previous quarter's $116.2M loss.
Operating cash flow was −$67.4M. Non-cash charges added back $3.4M of depreciation and amortization and $14.9M of share-based compensation. Working capital and other items added $25.9M. Capital expenditures of $7.5M exceeded it, leaving free cash flow of −$74.9M.
Questions
What was Iovance Biotherapeutics' revenue in the second quarter 2025?
Iovance Biotherapeutics (IOVA) reported revenue of $60.0M for the second quarter 2025 (Q2 2025), +93% from a year earlier and +22% from the quarter before.
Was Iovance Biotherapeutics profitable in the second quarter 2025?
Operating loss was $114M (-189.8% of revenue) and net loss $112M.